Kępczyńska Katarzyna, Zajda Małgorzata, Lewandowski Zbigniew, Przedlacki Jerzy, Zakrzewska-Pniewska Beata
Department of Neurology, Medical University of Warsaw, Warsaw, Poland.
Department of Neurology, Medical University of Warsaw, Warsaw, Poland.
Neurol Neurochir Pol. 2016 Jul-Aug;50(4):251-7. doi: 10.1016/j.pjnns.2016.04.010. Epub 2016 Apr 27.
Vitamin D (VD), an important factor for bone health immobilization and immune regulation, has been shown to have low serum concentration in multiple sclerosis (MS) patients. Those patients have also multiple fracture risk factors, including progressive immobilization and long-term glucocorticoids treatment. The aim of the study was to analyze bone health (osteopenia or osteoporosis prevalence) and VD serum concentration in MS patients as well as the influence of disease activity and treatment on bone health.
The study involved 72 MS patients: 52 women and 20 men. Mean age was 40.3±10.5 yrs, mean EDSS (Expanded Disability Status Scale) 3.3±1.9. Bone health was analyzed using standard densitometry in the lumbar spine and femoral neck. Serum levels of VD, calcium, phosphate and parathormone were assessed. We compared two groups of patients with multiple sclerosis: relapsing - remitting MS (RRMS) and progressive relapsing MS (PRMS).
Densitometry revealed osteopenia in twenty-six (36.1%) patients and osteoporosis in eleven (15.3%), no bone fractures were presented. Sixty-eight MS patients (94.4%) had lower VD serum level if compared to population referential values. Thirteen patients (18.1%) had severe VD deficiency. Densitometry parameter (T-score of the lumbar spine) worsened with EDSS increase (r=-0.43, P=0.001). There was a statistically significant negative correlation between VD concentration and EDSS score (r=-0.31; P=0.009).
Our study indicates that patients with MS have high incidence of osteopenia and osteoporosis and vitamin D deficiency. Bone health disturbances studied by densitometry are related to the disability caused by MS.
维生素D(VD)是骨骼健康固定和免疫调节的重要因素,已被证明在多发性硬化症(MS)患者中血清浓度较低。这些患者也有多种骨折风险因素,包括进行性固定和长期糖皮质激素治疗。本研究的目的是分析MS患者的骨骼健康(骨量减少或骨质疏松症患病率)和VD血清浓度,以及疾病活动和治疗对骨骼健康的影响。
本研究涉及72例MS患者:52例女性和20例男性。平均年龄为40.3±10.5岁,平均扩展残疾状态量表(EDSS)评分为3.3±1.9。使用标准骨密度测定法分析腰椎和股骨颈的骨骼健康状况。评估VD、钙、磷和甲状旁腺激素的血清水平。我们比较了两组多发性硬化症患者:复发缓解型MS(RRMS)和进展复发型MS(PRMS)。
骨密度测定显示26例(36.1%)患者存在骨量减少,11例(15.3%)患者存在骨质疏松症,未出现骨折。与人群参考值相比,68例MS患者(94.4%)的VD血清水平较低。13例患者(18.1%)存在严重VD缺乏。骨密度测定参数(腰椎T值)随EDSS增加而恶化(r=-0.43,P=0.001)。VD浓度与EDSS评分之间存在统计学显著负相关(r=-0.31;P=0.009)。
我们的研究表明,MS患者骨量减少和骨质疏松症以及维生素D缺乏的发生率较高。通过骨密度测定研究的骨骼健康障碍与MS所致残疾有关。